Skip to main content
    S

    Scynexis Inc (SCYX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $2.85
    -0.06 (-2.06%)

    Market Cap: $31.95M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Scynexis Inc (SCYX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Scynexis (SCYX) has a market cap of $31.95M and an enterprise value of $24.27M. Revenue grew 543.96% over the last 12 months from the 12 months before. It kept -53.50% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 24.03% below the market cap, as cash exceeds debt.

    Market Cap$31.95M
    Enterprise Value$24.27M
    Latest price (Nov 17, 2026)$2.85

    Key Dates

    The next earnings report is expected on Mar 2, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 2, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.16% in the quarter ended Sep 30, 2026.

    Shares Outstanding11.84M
    Shares Change (QoQ)+0.16%

    Valuation Ratios

    Sales and book value multiples are 1.8x and 0.6x. Its year-end P/S ranged from 0.8x to 384.4x from 2016 to 2025.

    P/S Ratio1.8x
    Forward P/S81.2x
    P/B Ratio0.6x

    Valuation history and multiples

    Price Statistics

    The stock is down 39.19% over 52 weeks and trades 30.66% below its 50-day average.

    Beta (1Y)1.63
    52-Week Change-39.19%
    1-Month Change-22.13%
    3-Month Change-44.66%
    6-Month Change-45.76%
    5-Year Change-90.59%
    10-Year Change-98.53%
    Total Return (1Y)-39.19%
    Total Return (3Y CAGR)-39.63%
    Total Return (5Y CAGR)-43.51%
    Return vs SPY (1Y)-50.12%
    Max Drawdown (1Y)-67.91%
    Max Drawdown (3Y)-87.14%
    Sharpe Ratio (1Y)-0.66
    Correlation with SPY (1Y)0.30
    50-Day Average$4.11
    200-Day Average$5.40
    52-Week Range$2.84 to $9.12
    RSI (14 Days)25.5
    Average Volume (20 Days)67.55K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 7.57x current liabilities, and total debt is 0.01x shareholder equity.

    Current Ratio7.57x
    Quick Ratio7.57x
    Debt / Equity0.01x
    Interest Coverage11.32x

    Returns and Efficiency

    Return on invested capital is -16.41% over the last 12 months, against a 5-year average of -28.16%.

    Return on Equity (ROE)-17.11%
    Return on Assets (ROA)-14.87%
    Return on Invested Capital (ROIC)-16.41%
    ROA (5Y Average)-16.96%
    ROIC (5Y Average)-28.16%
    Asset Turnover0.32x

    Scores

    SCYX has an Altman Z-Score of -5.67, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score-5.67
    Altman Z ZoneDistress
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $18.88M over the last 12 months.

    Revenue$18.88M
    Revenue Growth (YoY)+543.96%
    Gross Profit$18.88M
    Operating Income-$23.97M
    Pretax Income$11.20M
    Net Income-$10.10M
    Reported EPS (TTM)-$2.39

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 86.90% of the $67.95M in total assets.

    Cash and Equivalents$8.23M
    Total Debt$549.00K
    Net Cash$7.68M
    Net Cash Per Share$0.65
    Working Capital$43.70M
    Shareholder Equity$59.05M
    Book Value Per Share$4.99
    Total Assets$67.95M
    Total Liabilities$8.90M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$12.05M
    FCF Per Share-$1.21
    Depreciation and Amortization$246.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -126.97%.

    Gross Margin100.00%
    Operating Margin-126.97%
    Pretax Margin59.30%
    Net Margin-53.50%
    Gross Margin (5Y Average)97.77%

    Dividends and Yields

    SCYX does not pay a dividend.

    Buyback Yield-109.34%
    Shareholder Yield-109.34%

    Stock Splits

    The last split was a 1-for-8 reverse split on Jun 1, 2026.

    Last Split DateJun 1, 2026
    Split TypeReverse split
    Split Ratio1:8

    Peer Position

    Against 7 similar companies, SCYX has the 4th highest P/S and the 4th highest ROIC.

    P/S Ratio1.8x vs 1.6x median
    ROIC-16.41% vs -18.14% median
    Revenue Growth (Trailing 4 Quarters, YoY)+543.96% vs -7.46% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -31.43% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-31.43%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About SCYX

    What is SCYX's market cap?

    Scynexis has a market cap of $31.95M. Its enterprise value, which adds debt and subtracts cash, is $24.27M.

    How many shares of SCYX are outstanding?

    Scynexis has 11.84M shares outstanding.

    Does SCYX pay a dividend?

    No. Scynexis does not pay a dividend.

    How much debt does SCYX have?

    Scynexis has $549.00K of total debt and $8.23M of cash and equivalents, a net cash position of $7.68M.